Scalp to shins relief with expert tips - Itching to know what’s causing that scratch? Learn how hydration, barrier repair, ...

Discover how thyroid disorders affect your hair growth cycle, why testing matters, and what to expect during recovery from ...

I want to share my dementia story with others and bring attention to the brilliant services available, says Michaela Williams ...

I’ve had to have a number of medical tests over the last month. Just in case you didn’t see the billboards I plastered all ...

I find myself celebrating Asian American and Pacific Islander Heritage Month in the most delicious and radiant way possible—through the transformative AAPI-founded beauty and culinary treasures that ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.